Immutep to present positive results in melanoma trial

Company News

by Rachael Jones

Biotech company Immutep (ASX:IMM) today announces more mature data relating to Part B of its ongoing phase I TACTImel clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in patients with melanoma.

Consistent with previous data reported at 6 months of combination treatment, patients in Part B continue to report positive results in terms of tumour reductions after 9 months of treatment.

The data will be presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 in London today.

The ongoing TACTI-mel trial evaluates the combination of efti with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 24 patients with unresectable or metastatic melanoma.

Shares in Immutep (ASX:IMM) are trading 3.45 per cent higher at 3 cents. 
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.